The effect of the 3- (2-phenylethyl) -2-thioxo-1,3-thiazolidin-4-one clathrate complex with betadex on protein metabolism, growth and development of Wistar

Abstract

The clathrate complex of 3- (2-phenylethyl) -2-thioxo-1,3 thiazolidin-4-one with betadex was developed for the first time. 1: 5 ratio obtained by the solid-phase synthesis method, which has a crystalline form in the form of nanoparticles with an average size of 40.5 nm. In the present work, the effect of the created nanoscale form of 3- (2-phenylethyl) -2-thioxo-1,3 thiazolidin-4-one on protein metabolism, growth and development of Wistar rats was first studied. It was shown that the administration of 3- (2-phenylethyl) -2-thioxo-1,3 thiazolidin-4-one nanosized form in rats at doses of 10.0 and 20.0 mg / kg body weight activates the biosynthetic system and promotes an increase in protein deposition in their body. Nitrogen retention in rats of the experimental groups compared with the control increased by 20.0% (P≤0.05) due to a decrease in its endogenous losses, and the urea content in the blood serum was lower by 24.1 and 26.4%, respectively, compared to control. In rats of the experimental groups, the concentration of total protein (P≤0.05), albumin (P≤0.05) and globulins in the blood was higher compared to the control. It was found that in female rats of the experimental groups, in comparison with the control and intact animals, their growth and development were statistically significantly higher. In this case, the optimal dose of the nanoscale form of 3- (2 – phenylethyl) -2-thioxo-1,3 thiazolidin-4-one is a dose of 10.0 mg / kg of rat body weight.